Pfizer released trial data for its new obesity drug, raising questions about patient tolerability as company shares drop by over 3%. Despite potential side effects, Pfizer plans to advance numerous ...
SAN FRANCISCO -- As more people are eligible to get vaccinated, reports of side effects after the second Pfizer and Moderna shots are surfacing. Dr. Robert Wachter, chief of medicine at UCSF says many ...
Stocktwits on MSN
Pfizer reports positive weight-loss trial results, strong Q4 – so why is PFE stock falling?
Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes. ・The company plans to launch more than 20 trials in 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results